Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPLENEVAC-2 pneumococcal revaccination in splenectomized adults
2018-003068-29Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2018
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in invasive pneumococcal disease (IPD) comparing PCV13 then PPS23 with PPS23 alone (2 arms). Primary endpoint: Month 13 serologic response rate. Started Sep 2018; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on 2018-003068-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003068-29.